Drugs / MVA-BN-CV301
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04574583 | Nov 2020 → Feb 2023 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03376659 | Aug 2018 → Aug 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Georgetown University | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04491955 | Sep 2020 → Oct 2022 | colorectal cancer, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03628716 | Sep 2018 → Nov 2020 | urinary bladder cancer | Bavarian Nordic | Completed | No outcome recorded |
| Phase 2 | NCT03547999 | Jun 2018 → Mar 2024 | colorectal cancer | Patrick Boland | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-CV301 | “MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)” NCT03376659 ↗4“Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22.” NCT03628716 ↗ “CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301.” NCT04491955 ↗ |
| Modality | Vaccine | “The experimental arm will first be treated with 2 vaccinations of MVA-BN-CV301 given two weeks apart (Days -28, -14)” NCT03547999 ↗ |
| Route | Subcutaneous | “given subcutaneously (s.c.)” NCT03376659 ↗ |